Taking advantage of a broken patent system, Big Pharma is making minor tweaks to medications just to keep affordable generics ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Amycretin, the Danish drugmaker’s next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug ...

Deep Apple discovers drug candidates using its AI-based platform that screens virtual libraries of billions of compounds to ...

COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug ...

The London-based fund, which has targeted budget airline Ryanair and Italian bank UniCredit, wants to influence the ...

CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

All three major averages closed out May with sizable gains Friday, with the S&P 500 and Nasdaq Composite seeing their best month since November 2023.

The maker of weight loss drugs Ozempic and Wegovy broke rules around the advertising and marketing of its medication to healthcare workers over three years, the medicines watchdog has found.

Novo Nordisk (NVO) is offering a one-month reduction ... drugs and are seeking access to authentic, FDA-approved Wegovy," the company said in a statement Thursday. Semaglutide is the key ...